Home / Resources and Insights / Oligonucleotide Drug Development (CMC)
Oligonucleotide Drug Development (CMC)
Less than 1 min read time
This two-part webinar series explores recent developments in oligonucleotide chemistry, biology, DMPK, toxicological assessment, manufacture, and formulation.
Part 2: Oligonucleotide Drug Development (CMC)
* Explore synthesis strategies and analytical methodologies
* Compare the advantages and disadvantages of different formulation strategies
* Review the latest CMC strategies and regulatory framework
Gated content
Please complete the form below to access this content.
Related Reading
Accelerating Novel Peptides into Clinical Trials with Integrated Partnership
Do you have peptide drug candidates in development?
Overcoming Key Challenges in PROTAC Drug Development
Pharmaceutical development of PROTAC (Proteolysis Targeting Chimeras) molecules presents significant challenges due to their complex molecular structures, leading to low...
